The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...

COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new ...

These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.

The authors compared outcomes among adults just under 70 years who were not prescribed Paxlovid to those who were given the ...

A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

In the fourth quarter, a larger-than-expected sales haul of $4.1 billion from Pfizer's COVID vaccine Cominaty and its antiviral Paxlovid helped drive the company’s total revenue of $17.8 billion ...

You have $1,000 (or $200 or $50,000) burning a hole in your pocket and you're itching to invest in some stocks. Verizon ...